You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents

    SBC: Stemsynergy Therapeutic            Topic: 102

    PROJECT SUMMARY/ABSTRACT The MYC family proteins are comprised of three paralogs termed c-myc, N-myc, and L-myc. The MYC proteins play a fundamental role in cell proliferation and oncogenesis by regulating cellular processes such as gene transcription, protein translation, cell cycle progression, and cell death. While N-myc and L-myc drive oncogenesis in a small number of cancer types, the require ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: NHLBI

    ABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 Fast Track STTR application focuses on eNAMPT (extra- cellular nicotinamide phosphoribosyltransferase) as a novel, highly attractive PAH target. Aqualung Therapeutics has developed a humanized eNAMPT-neutralizing mAb, ALT-10 ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Novel non-narcotic analgesic for acute and chronic pain

    SBC: South Rampart Pharma, LLC            Topic: 106

    PROJECT SUMMARYSouth Rampart Pharma (SRP) is an early clinical-stage company focused on developing SRP-001, a novel non-opioid designed to treat moderate-to-severe acute and chronic pain without the dose-limiting hepatotoxicity of acetaminophen and nephrotoxicity of NSAIDs, and the misuse and addictive potential of opioids. SRP-001 is currently in Phase 1 trials where interim data support the expe ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NICHD

    Necrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of an electrical impedance myography (EIM) vaginal device for the evaluation of pelvic skeletal muscles

    SBC: BOLD TYPE LLC            Topic: NICHD

    1 Abstract2 Bold Type is developing the “SenseWand”, a wireless pelvic floor diagnostic system (device and app)3 to evaluate pelvic floor muscle health using electrical impedance myography (EIM). PFDs are complex4 conditions (e.g. pelvic organ prolapse, stress urinary incontinence, high tone pelvic floor dysfunction) that impact5 millions of women worldwide. It is estimated that PFDs will affe ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites

    SBC: EMMUNE INC            Topic: R

    We are developing vaccine antigens for SARS-CoV-2 that focus the antibody response onto neutralizing epitopes in the receptor binding domain (RBD) of the viral Spike (S) protein. Booster antigens derived from variants of SARS-CoV-2 would especially benefit from being limited to the RBD, due to the preponderance of conserved but non-neutralizing epitopes in the full-length S protein. However, RBD-o ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Advanced Automated Inventory Technology Utilizing SOUND

    SBC: THE TONE KNOWS INC            Topic: DLA232005

    The TONE Knows Inc. ("TONE") will develop next-generation warehouse inventory management, verification, location, and reconciliation utilizing our patented "audio QR Code" technology. This technology allows for the continuous monitoring, tracking, and accounting for every single item stored in a DLA DC, external storage areas, in-theater Distribution Centers, or forward storage facilities, util ...

    SBIR Phase I 2023 Department of DefenseDefense Logistics Agency
  9. Army Wire Harness Replacement Activity

    SBC: BASCOM HUNTER TECHNOLOGIES INC            Topic: DLA232001

    The United States Army has requested interest parties submit proposals to become approved suppliers for three wire harness assemblies, part numbers 10033768, 10024853, and 12574943.  The past manufacturers of these products will no longer produce the item. Without a viable supply chain in place, the readiness of the Army could be placed at risk. Bascom Hunter Technologies, Inc has the technical ...

    SBIR Phase I 2023 Department of DefenseDefense Logistics Agency
  10. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: 100

    Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with an incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The α7β1 integrin is a transmembrane linkage system in skeletal and card ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government